GB2370571B - A modified 5t4 antigen - Google Patents

A modified 5t4 antigen

Info

Publication number
GB2370571B
GB2370571B GB0127669A GB0127669A GB2370571B GB 2370571 B GB2370571 B GB 2370571B GB 0127669 A GB0127669 A GB 0127669A GB 0127669 A GB0127669 A GB 0127669A GB 2370571 B GB2370571 B GB 2370571B
Authority
GB
United Kingdom
Prior art keywords
antigen
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0127669A
Other versions
GB2370571A (en
GB0127669D0 (en
Inventor
Miles William Carroll
Kevin Alan Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9825303.2A external-priority patent/GB9825303D0/en
Priority claimed from GBGB9901739.4A external-priority patent/GB9901739D0/en
Priority claimed from GBGB9917995.4A external-priority patent/GB9917995D0/en
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Priority to GB0224538A priority Critical patent/GB2378704B/en
Priority claimed from GB0014986A external-priority patent/GB2347932B/en
Publication of GB0127669D0 publication Critical patent/GB0127669D0/en
Publication of GB2370571A publication Critical patent/GB2370571A/en
Application granted granted Critical
Publication of GB2370571B publication Critical patent/GB2370571B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GB0127669A 1998-11-18 1999-11-18 A modified 5t4 antigen Expired - Fee Related GB2370571B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0224538A GB2378704B (en) 1998-11-18 1999-11-18 Uses of 5t4 antigen

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9825303.2A GB9825303D0 (en) 1998-11-18 1998-11-18 Vector
GBGB9901739.4A GB9901739D0 (en) 1999-01-27 1999-01-27 Polypeptide
GBGB9917995.4A GB9917995D0 (en) 1999-07-30 1999-07-30 Polypeptide
GB0014986A GB2347932B (en) 1998-11-18 1999-11-18 Vectors for the delivery of 5T4 antigen

Publications (3)

Publication Number Publication Date
GB0127669D0 GB0127669D0 (en) 2002-01-09
GB2370571A GB2370571A (en) 2002-07-03
GB2370571B true GB2370571B (en) 2003-05-07

Family

ID=27447855

Family Applications (3)

Application Number Title Priority Date Filing Date
GB0127673A Expired - Fee Related GB2370572B (en) 1998-11-18 1999-11-18 Use of a professional antigen presenting cell
GB0127669A Expired - Fee Related GB2370571B (en) 1998-11-18 1999-11-18 A modified 5t4 antigen
GB0127675A Withdrawn GB2370573A (en) 1998-11-18 1999-11-18 Poxviral vectors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB0127673A Expired - Fee Related GB2370572B (en) 1998-11-18 1999-11-18 Use of a professional antigen presenting cell

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB0127675A Withdrawn GB2370573A (en) 1998-11-18 1999-11-18 Poxviral vectors

Country Status (1)

Country Link
GB (3) GB2370572B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1335987T4 (en) 2000-11-23 2016-09-19 Bavarian Nordic As Modified variant of vaccinia virus Ankara
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
CN101397574A (en) 2001-12-04 2009-04-01 巴法里安诺迪克有限公司 Flavivirus NS1 subunit vaccine
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203419D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
DE60314823T3 (en) 2002-04-19 2017-11-16 Bavarian Nordic A/S MODIFIED VARIANT OF VACCINIA ANKARA VIRUS AS VACCINE FOR NEWBORN
ATE393212T2 (en) 2002-09-05 2008-05-15 Bavarian Nordic As METHOD FOR AMPLIFICATION OF A POXVIRUS IN SERUM-FREE CONDITIONS
PA8718601A1 (en) 2006-03-10 2009-05-15 Wyeth Corp ANTI-5T4 ANTIBODIES AND THEIR USES
WO2008059252A2 (en) * 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
AU2018235130B2 (en) 2017-03-15 2023-12-07 Oxford Biomedica (Uk) Limited Method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007947A1 (en) * 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
EP0840622A4 (en) * 1995-07-21 2003-01-02 Aventis Pharma Inc Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007947A1 (en) * 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Biol Chem; Vol 269, pp 9319-9324 (1994). Myers et al. *

Also Published As

Publication number Publication date
GB0127675D0 (en) 2002-01-09
GB2370573A (en) 2002-07-03
GB2370572B (en) 2003-05-07
GB2370572A (en) 2002-07-03
GB0127673D0 (en) 2002-01-09
GB2370571A (en) 2002-07-03
GB0127669D0 (en) 2002-01-09

Similar Documents

Publication Publication Date Title
GB9809839D0 (en) Antibody
GB2370571B (en) A modified 5t4 antigen
HUP9800744A3 (en) Antibodies against fas-antigene
GB2335134B (en) A beverage
GB2333690B (en) A head-guard
GB9818915D0 (en) Antibodies
GB9828700D0 (en) Antibody
GB2353350B (en) A beverage
GB0126685D0 (en) A beverage
GB9825184D0 (en) Antigen
HUP9900288A3 (en) Overlapping connection
GB9819411D0 (en) Antibodies
GB9915419D0 (en) Antigens
GB9726147D0 (en) Antigens
GB9800760D0 (en) Antigens
GB9814792D0 (en) A boardgame
GB9822143D0 (en) Antigens
GB9819015D0 (en) Antigens
GB9917334D0 (en) A cracker
GB9814330D0 (en) Electrofusion weldpiece
GB9701487D0 (en) Antigens
AU139238S (en) A tallboy
GB9812315D0 (en) A didgeridoo
AU137152S (en) A bidette
AU134702S (en) A pareo

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20171118